Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
Preliminary data from a study conducted at the University of Oxford suggests that the COVID-19 vaccine developed by AstraZeneca PLC is successful against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters on Friday.
The data suggests that the vaccine won’t need to be modified so as to protect against the variant, which is thought to have originated from the Amazonian city of Manaus, said the source, who requested anonymity as the results haven’t yet been made public.
The source did not provide the specific efficacy of the vaccine against the variant. They said the complete results of the study should be published shortly, maybe in March.
Early results indicated the AstraZeneca vaccine was less effective against the South African variant, which is very similar to P1. South Africa then stopped the usage of the vaccine in the country.
The information comes as a small-sample study indicated the COVID-19 vaccine developed by China’s Sinovac may not work effectively against the Brazilian variant.
Responding to a request for comment, Fiocruz, which delivered the samples that formed the basis of the research, told Reuters it did not have any information on the study, as it had been led by AstraZeneca and the University of Oxford.
Agents for AstraZeneca and the University of Oxford did not immediately respond to requests for comment.
Brazil is presently confronting a brutal and long-term second wave of the coronavirus, hitting a daily record of 1,910 deaths on Wednesday.
The P1 variant is one of the things that epidemiologists believe is contributing to a rise in deaths and cases, and there’s been concern in the scientific community about the variant’s resistance to vaccines.
